Current Strategies and Recent Advances in the Therapy of Hypercholesterolemia

Atherosclerosis Supplements

Volumn 10, Issue 5, 2009, Pages 1-4

  Windler, E ^a   Zyriax, B Chr ^a   Bamberger, Chr ^a   Rinninger, F ^a   Beil, F U ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Drug therapy; HDL cholesterol; Hypercholesterolemia; LDL cholesterol; Lipid lowering therapy; Raising HDL cholesterol

Indexed keywords

COLESEVELAM; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAROPIPRANT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MIPOMERSEN; NICOTINIC ACID; NICOTINIC ACID PLUS SIMVASTATIN; PHYTOSTEROL; ROSUVASTATIN; TORCETRAPIB;

ADD ON THERAPY; ANTISENSE THERAPY; APHERESIS; ARTICLE; BEDTIME DOSAGE; CHOLESTEROL SYNTHESIS; DRUG EFFECT; DRUG MECHANISM; DRUG TOLERABILITY; FLUSHING; HUMAN; HYPERCHOLESTEROLEMIA; INTESTINE ABSORPTION; LIPID ABSORPTION; PRIORITY JOURNAL; SIDE EFFECT;

ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; HUMANS; HYPERCHOLESTEROLEMIA; TREATMENT OUTCOME;

EID: 72649101370     PISSN: 15675688     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5688(09)00065-8     Document Type: Article

References (21)

1. 4S Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
2. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., Brown L., Warnica J.W., Arnold J.M., Wun C.C., Davis B.R., and Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 335 (1996) 1001-1009
3. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
4. Cohen J.C., Boerwinkle E., Mosley Jr. T.H., and Hobbs H.H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 354 (2006) 1264-1272
5. Sever P.S., Dahlöf B., Poulter N.R., Wedel H., Beevers G., Caulfield M., Collins R., Kjeldsen S.E., Kristinsson A., McInnes G.T., Mehlsen J., Nieminen M., O'Brien E., Ostergren J., and ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361 (2003) 1149-1158
6. Colhoun H.M., Betteridge D.J., Durrington P.N., Hitman G.A., Neil H.A., Livingstone S.J., Thomason M.J., Mackness M.I., Charlton-Menys V., Fuller J.H., and CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364 (2004) 685-696
7. Ridker P.M., Danielson E., Fonseca F.A., Genest J., Gotto Jr. A.M., Kastelein J.J., Koenig W., Libby P., Lorenzatti A.J., MacFadyen J.G., Nordestgaard B.G., Shepherd J., Willerson J.T., Glynn R.J., and JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359 (2008) 2195-2207
8. Pandor A., Ara R.M., Tumur I., Wilkinson A.J., Paisley S., Duenas A., Durrington P.N., and Chilcott J. Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials. J Intern Med 265 (2009) 568-580
9. Demonty I., Ras R.T., van der Knaap H.C., Duchateau G.S., Meijer L., Zock P.L., Geleijnse J.M., and Trautwein E.A. Continuous dose-response relationship of the LDL-cholesterol-lowering effect of phytosterol intake. J Nutr 139 (2009) 271-284
10. Corsini A., Windler E., and Farnier M. Colesevelam hydrochloride: usefulness of a specifically engineered bile acid sequestrant for lowering LDL-cholesterol. Eur J Cardiovasc Prev Rehabil 16 (2009) 1-9
11. Davidson M.H., Dillon M.A., Gordon B., Jones P., Samuels J., Weiss S., Isaacsohn J., Toth P., and Burke S.K. Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch Intern Med 159 (1999) 1893-1900
12. Fonseca V.A., Rosenstock J., Wang A.C., Truitt K.E., and Jones M.R. Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care 31 (2008) 1479-1484
13. Kastelein J.J., Wedel M.K., Baker B.F., Su J., Bradley J.D., Yu R.Z., Chuang E., Graham M.J., and Crooke R.M. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an anti sense inhibitor of apolipoprotein B. Circulation 114 (2006) 1729-1735
14. Barter P.J., Caulfield M., Eriksson M., Grundy S.M., Kastelein J.J., Komajda M., Lopez-Sendon J., Mosca L., Tardif J.C., Waters D.D., Shear C.L., Revkin J.H., Buhr K.A., Fisher M.R., Tall A.R., Brewer B., and ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357 (2007) 2109-2122
15. Tall A.R. CETP inhibitors to increase HDL cholesterol levels. N Engl J Med 356 (2007) 1364-1366
16. de Grooth G.J., Kuivenhoven J.A., Stalenhoef A.F., de Graaf J., Zwinderman A.H., Posma J.L., van Tol A., and Kastelein J.J. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation 105 (2002) 2159-2165
17. Rubins H.B., Robins S.J., Collins D., Fye C.L., Anderson J.W., Elam M.B., Faas F.H., Linares E., Schaefer E.J., Schectman G., Wilt T.J., and Wittes J. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341 (1999) 410-418
18. Canner P.L., Berge K.G., Wenger N.K., Stamler J., Friedman L., Prineas R.J., and Friedewald W. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 8 (1986) 1245-1255
19. Chapman M.J., Assmann G., Fruchart J.C., Shepherd J., Sirtori C., and European Consensus Panel on HDL-C. Raising high-density lipo-protein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid-a position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin 20 (2004) 1253-1268
20. Maccubbin D., Koren M.J., Davidson M., Gavish D., Pasternak R.C., Macdonell G., Mallick M., Sisk C.M., Paolini J.F., and Mitchel Y. Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease. Am J Cardiol 104 (2009) 74-81
21. Maccubbin D., Bays H.E., Olsson A.G., Elinoff V., Elis A., Mitchel Y., Sirah W., Betteridge A., Reyes R., Yu Q., Kuznetsova O., Sisk C.M., Pasternak R.C., and Paolini J.F. Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hyper-cholesterolaemia or mixed dyslipidaemia. Int J Clin Pract 62 (2008) 1959-1970